PROPHASE LABS INC (PRPH) Stock Overview
USA - NASDAQ:PRPH - US74345W1080 - Common Stock
PRPH Key Statistics, Chart & Performance
The current stock price of PRPH is 0.3855 USD. In the past month the price decreased by -15.79%. In the past year, price decreased by -81.99%.
PRPH Latest News, Press Relases and Analysis
PRPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.78 | 776.19B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.61 | 256.13B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.95 | 238.94B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.38 | 231.28B | ||
| MRK | MERCK & CO. INC. | 11.3 | 217.38B | ||
| PFE | PFIZER INC | 7.23 | 139.30B | ||
| SNY | SANOFI-ADR | 11.55 | 124.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 87.16B | ||
| GSK | GSK PLC-SPON ADR | 9.75 | 87.89B | ||
| ZTS | ZOETIS INC | 23.38 | 64.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.36 | 44.53B |
Related stock screener links
About PRPH
Company Profile
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Company Info
PROPHASE LABS INC
711 Stewart Ave, Suite 200, Garden City
New York City NEW YORK 11530 US
CEO: Ted Karkus
Employees: 96
Phone: 12153450919
PROPHASE LABS INC / PRPH FAQ
What does PROPHASE LABS INC do?
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
What is the stock price of PROPHASE LABS INC today?
The current stock price of PRPH is 0.3855 USD. The price increased by 2.61% in the last trading session.
What is the dividend status of PROPHASE LABS INC?
PRPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRPH stock?
PRPH has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is PROPHASE LABS INC (PRPH) stock traded?
PRPH stock is listed on the Nasdaq exchange.
What is the ex-dividend date for PRPH stock?
The next ex-dividend date for PROPHASE LABS INC (PRPH) is May 24, 2022.
Can you provide the growth outlook for PROPHASE LABS INC?
The Revenue of PROPHASE LABS INC (PRPH) is expected to grow by 64.06% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
PRPH Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PRPH. When comparing the yearly performance of all stocks, PRPH is a bad performer in the overall market: 94.4% of all stocks are doing better.
PRPH Financial Highlights
Over the last trailing twelve months PRPH reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by -80.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -126.93% | ||
| ROE | -466.63% | ||
| Debt/Equity | 0.45 |
PRPH Forecast & Estimates
7 analysts have analysed PRPH and the average price target is 16.32 USD. This implies a price increase of 4133.46% is expected in the next year compared to the current price of 0.3855.
For the next year, analysts expect an EPS growth of 75.59% and a revenue growth 64.06% for PRPH